CD

Chromadex CorpNASDAQ CDXC Stock Report

Last reporting period 30 Sep, 2024

Updated 20 Nov, 2024

Last price

Market cap $B

0.287

Micro

Exchange

XNAS - Nasdaq

CDXC Stock Analysis

CD

Uncovered

Chromadex Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

90/100

Moderate score

Market cap $B

0.287

Dividend yield

Shares outstanding

74.838 B

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 113 full-time employees. The company went IPO on 2007-06-25. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain its ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company provides Niagen in ingredient form to its strategic partners. The company provides Niagen in ingredient form to its strategic partners. The company also offers Immulina, which is a spirulina extract. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.

View Section: Eyestock Rating